Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats

Harshini Neelakantan, Erica D. Holliday, Robert G. Fox, Sonja J. Stutz, Sandra D. Comer, Margaret Haney, Noelle C. Anastasio, F. Gerard Moeller, Kathryn A. Cunningham

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Opioid use disorder (OUD) is a major public health problem. High relapse rates and poor treatment retention continue to pose major challenges in OUD treatment. Of the abused opioids, oxycodone is well described to maintain self-administration and evoke the durable conditioned responses ("cue reactivity") that result from pairing of opioid-related stimuli (e.g., paraphernalia) with repeated abuse. Serotonin (5-HT) neurotransmission, particularly through the 5-HT2C receptor (5-HT2CR), regulates psychostimulant reward and cue reactivity, and in the present experiments, we investigated the hypothesis that the selective 5-HT2CR agonist lorcaserin, which is approved by the United States Food and Drug Administration (FDA) for the treatment of obesity, will suppress oxycodone self-administration and oxycodone-associated cue reactivity in rats. We found that lorcaserin inhibited oxycodone intake, an effect blocked by the selective 5-HT2CR antagonist SB242084. Lorcaserin also decreased responding for the discrete cue complex ("cue reactivity") previously associated with delivery of oxycodone (i.e., stimulus lights, infusion pump sounds) in both abstinence and extinction-reinstatement models. The selected dose range of lorcaserin (0.25-1 mg/kg) does not overtly alter spontaneous behaviors nor operant responding on inactive levers in the present study. Taken together, the ability of lorcaserin to reduce the oxycodone self-administration and decrease cue reactivity associated with relapse highlights the therapeutic potential for lorcaserin in the treatment of OUD.

Original languageEnglish (US)
Pages (from-to)1065-1073
Number of pages9
JournalACS Chemical Neuroscience
Volume8
Issue number5
DOIs
StatePublished - May 17 2017

Fingerprint

Oxycodone
Self Administration
Cues
Rats
Opioid Analgesics
Receptor, Serotonin, 5-HT2C
Recurrence
Serotonin
Serotonin 5-HT2 Receptor Agonists
Serotonin 5-HT2 Receptor Antagonists
Therapeutics
Infusion Pumps
Aptitude
Public health
United States Food and Drug Administration
Medical problems
Reward
Synaptic Transmission
lorcaserin
Public Health

Keywords

  • 5-HT2C receptor
  • cue reactivity
  • lorcaserin
  • opioid
  • oxycodone
  • self-administration

ASJC Scopus subject areas

  • Physiology
  • Biochemistry
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats. / Neelakantan, Harshini; Holliday, Erica D.; Fox, Robert G.; Stutz, Sonja J.; Comer, Sandra D.; Haney, Margaret; Anastasio, Noelle C.; Moeller, F. Gerard; Cunningham, Kathryn A.

In: ACS Chemical Neuroscience, Vol. 8, No. 5, 17.05.2017, p. 1065-1073.

Research output: Contribution to journalArticle

Neelakantan, Harshini ; Holliday, Erica D. ; Fox, Robert G. ; Stutz, Sonja J. ; Comer, Sandra D. ; Haney, Margaret ; Anastasio, Noelle C. ; Moeller, F. Gerard ; Cunningham, Kathryn A. / Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats. In: ACS Chemical Neuroscience. 2017 ; Vol. 8, No. 5. pp. 1065-1073.
@article{c39df9d2824a459b979d2eb2e3840354,
title = "Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats",
abstract = "Opioid use disorder (OUD) is a major public health problem. High relapse rates and poor treatment retention continue to pose major challenges in OUD treatment. Of the abused opioids, oxycodone is well described to maintain self-administration and evoke the durable conditioned responses ({"}cue reactivity{"}) that result from pairing of opioid-related stimuli (e.g., paraphernalia) with repeated abuse. Serotonin (5-HT) neurotransmission, particularly through the 5-HT2C receptor (5-HT2CR), regulates psychostimulant reward and cue reactivity, and in the present experiments, we investigated the hypothesis that the selective 5-HT2CR agonist lorcaserin, which is approved by the United States Food and Drug Administration (FDA) for the treatment of obesity, will suppress oxycodone self-administration and oxycodone-associated cue reactivity in rats. We found that lorcaserin inhibited oxycodone intake, an effect blocked by the selective 5-HT2CR antagonist SB242084. Lorcaserin also decreased responding for the discrete cue complex ({"}cue reactivity{"}) previously associated with delivery of oxycodone (i.e., stimulus lights, infusion pump sounds) in both abstinence and extinction-reinstatement models. The selected dose range of lorcaserin (0.25-1 mg/kg) does not overtly alter spontaneous behaviors nor operant responding on inactive levers in the present study. Taken together, the ability of lorcaserin to reduce the oxycodone self-administration and decrease cue reactivity associated with relapse highlights the therapeutic potential for lorcaserin in the treatment of OUD.",
keywords = "5-HT2C receptor, cue reactivity, lorcaserin, opioid, oxycodone, self-administration",
author = "Harshini Neelakantan and Holliday, {Erica D.} and Fox, {Robert G.} and Stutz, {Sonja J.} and Comer, {Sandra D.} and Margaret Haney and Anastasio, {Noelle C.} and Moeller, {F. Gerard} and Cunningham, {Kathryn A.}",
year = "2017",
month = "5",
day = "17",
doi = "10.1021/acschemneuro.6b00413",
language = "English (US)",
volume = "8",
pages = "1065--1073",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats

AU - Neelakantan, Harshini

AU - Holliday, Erica D.

AU - Fox, Robert G.

AU - Stutz, Sonja J.

AU - Comer, Sandra D.

AU - Haney, Margaret

AU - Anastasio, Noelle C.

AU - Moeller, F. Gerard

AU - Cunningham, Kathryn A.

PY - 2017/5/17

Y1 - 2017/5/17

N2 - Opioid use disorder (OUD) is a major public health problem. High relapse rates and poor treatment retention continue to pose major challenges in OUD treatment. Of the abused opioids, oxycodone is well described to maintain self-administration and evoke the durable conditioned responses ("cue reactivity") that result from pairing of opioid-related stimuli (e.g., paraphernalia) with repeated abuse. Serotonin (5-HT) neurotransmission, particularly through the 5-HT2C receptor (5-HT2CR), regulates psychostimulant reward and cue reactivity, and in the present experiments, we investigated the hypothesis that the selective 5-HT2CR agonist lorcaserin, which is approved by the United States Food and Drug Administration (FDA) for the treatment of obesity, will suppress oxycodone self-administration and oxycodone-associated cue reactivity in rats. We found that lorcaserin inhibited oxycodone intake, an effect blocked by the selective 5-HT2CR antagonist SB242084. Lorcaserin also decreased responding for the discrete cue complex ("cue reactivity") previously associated with delivery of oxycodone (i.e., stimulus lights, infusion pump sounds) in both abstinence and extinction-reinstatement models. The selected dose range of lorcaserin (0.25-1 mg/kg) does not overtly alter spontaneous behaviors nor operant responding on inactive levers in the present study. Taken together, the ability of lorcaserin to reduce the oxycodone self-administration and decrease cue reactivity associated with relapse highlights the therapeutic potential for lorcaserin in the treatment of OUD.

AB - Opioid use disorder (OUD) is a major public health problem. High relapse rates and poor treatment retention continue to pose major challenges in OUD treatment. Of the abused opioids, oxycodone is well described to maintain self-administration and evoke the durable conditioned responses ("cue reactivity") that result from pairing of opioid-related stimuli (e.g., paraphernalia) with repeated abuse. Serotonin (5-HT) neurotransmission, particularly through the 5-HT2C receptor (5-HT2CR), regulates psychostimulant reward and cue reactivity, and in the present experiments, we investigated the hypothesis that the selective 5-HT2CR agonist lorcaserin, which is approved by the United States Food and Drug Administration (FDA) for the treatment of obesity, will suppress oxycodone self-administration and oxycodone-associated cue reactivity in rats. We found that lorcaserin inhibited oxycodone intake, an effect blocked by the selective 5-HT2CR antagonist SB242084. Lorcaserin also decreased responding for the discrete cue complex ("cue reactivity") previously associated with delivery of oxycodone (i.e., stimulus lights, infusion pump sounds) in both abstinence and extinction-reinstatement models. The selected dose range of lorcaserin (0.25-1 mg/kg) does not overtly alter spontaneous behaviors nor operant responding on inactive levers in the present study. Taken together, the ability of lorcaserin to reduce the oxycodone self-administration and decrease cue reactivity associated with relapse highlights the therapeutic potential for lorcaserin in the treatment of OUD.

KW - 5-HT2C receptor

KW - cue reactivity

KW - lorcaserin

KW - opioid

KW - oxycodone

KW - self-administration

UR - http://www.scopus.com/inward/record.url?scp=85019565733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019565733&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.6b00413

DO - 10.1021/acschemneuro.6b00413

M3 - Article

VL - 8

SP - 1065

EP - 1073

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 5

ER -